ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
PharmaEssentia resubmits BLA for polycythemia vera therapeutic
May 18, 2021US subsidiary of Taiwan, China-based PharmaEssentia has resubmitted its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) to obtain approval for ropeginterferon alfa-2b-njft for polycythemia vera (PV) treatment. -
PharmaEssentia Announces Favorable Two-year Results of Ropeginterferon Alfa-2b in Polycythemia Vera
December 12, 2017PharmaEssentia is currently working with the U.S. FDA for submission of a biologics license application (BLA) for Ropeginterferon alfa-2b for Polycythemia Vera (PV) in the U.S.
Pharma Sources Insight January 2025
